OverviewSuggest Edit

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. The Company's purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
TypePublic
Founded2002
HQSouth Brunswick Township, NJ, US
Websitecytosorbents.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Sept 2017)65
Revenue (FY, 2017)$15.2 M(+60%)
Share Price (Sept 2021)$8.3
Cybersecurity ratingAMore

Key People/Management at Cytosorbents

Phillip P. Chan

Phillip P. Chan

Chief Executive Officer and President
Alan D. Sobel

Alan D. Sobel

Director
Kathleen Bloch

Kathleen Bloch

Chief Financial Officer
Vincent Capponi

Vincent Capponi

Chief Operating Officer
Show more

Cytosorbents Office Locations

Cytosorbents has offices in South Brunswick Township and Berlin
South Brunswick Township, NJ, US (HQ)
7 Deerpark Dr, Monmouth Junction
Berlin, DE
Müggelseedamm 131
Show all (2)

Cytosorbents Financials and Metrics

Cytosorbents Revenue

Embed Graph
View revenue for all periods
Cytosorbents's revenue was reported to be $15.15 m in FY, 2017 which is a 59% increase from the previous period.
USD

Revenue (FY, 2017)

15.2m

Revenue growth (FY, 2016 - FY, 2017), %

59%

Gross profit (FY, 2017)

9.6m

Gross profit margin (FY, 2017), %

63.6%

Net income (FY, 2017)

(8.5m)

EBIT (FY, 2017)

(9.8m)

Market capitalization (23-Sept-2021)

358.2m

Closing stock price (23-Sept-2021)

8.3

Cash (31-Dec-2017)

17.3m

EV

350.9m
Cytosorbents's current market capitalization is $358.2 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

4.8m9.5m15.2m

Revenue growth, %

99%59%

Cost of goods sold

2.2m4.0m5.5m

Gross profit

2.6m5.6m9.6m
USDFY, 2015FY, 2016FY, 2017

Cash

5.3m5.2m17.3m

Accounts Receivable

648.9k1.4m2.2m

Prepaid Expenses

511.9k315.8k416.0k

Inventories

1.2m834.0k795.7k
USDFY, 2015FY, 2016FY, 2017

Net Income

(8.1m)(11.8m)(8.5m)

Depreciation and Amortization

113.0k161.6k218.3k

Inventories

(671.3k)340.4k57.3k

Accounts Payable

(83.2k)2.1m523.4k
USDFY, 2015

Financial Leverage

1.4 x
Show all financial metrics

Cytosorbents Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Cytosorbents Online and Social Media Presence

Embed Graph

Cytosorbents News and Updates

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., Sept. 10, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing...

CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the commercial launch of Aferetica's PerLife™ ex vivo organ perfusion...

CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE

MONMOUTH JUNCTION, N.J., July 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the...

CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit

MONMOUTH JUNCTION, N.J., May 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the...

CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world,...

CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference

MONMOUTH JUNCTION, N.J., March 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,...
Show more

Cytosorbents Blogs

CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

Upcoming international webinar on September 16, 2021 will summarize published clinical data from around the world on the use of CytoSorb in critically ill COVID-19 patients MONMOUTH JUNCTION, N.J., Sept. 14, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of li…

CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies

MONMOUTH JUNCTION, N.J., Sept. 13, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces key se…

CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

MONMOUTH JUNCTION, N.J., Sept. 8, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces a special Company webina…

Topline Results from CytoSorbents’ U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

90-day ICU Mortality was 27% with ECMO + CytoSorb in CTC Registry Data Presented on Day 1 of the International Symposium on Intensive Care and Emergency Medicine. For context, the Extracorporeal Life Support Organization COVID-19 ECMO Registry Reports 50% 90-day Mortality in North America with Stand…

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents’ DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

FDA Breakthrough Designation Granted to CytoSorbents’ DrugSorb-ATR for Removal of Apixaban and Rivaroxaban to Reduce the Risk of Serious Bleeding in Urgent Cardiothoracic Surgery MONMOUTH JUNCTION, N.J., Aug. 12, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment …

CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

Total revenue increased 23% to $12.0 million. Core non-COVID-19 product sales increased 38% Y-Y, driving overall Q2 2021 product sales to $11.4 million versus $9.5 million a year ago MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme…
Show more

Cytosorbents Frequently Asked Questions

  • When was Cytosorbents founded?

    Cytosorbents was founded in 2002.

  • Who are Cytosorbents key executives?

    Cytosorbents's key executives are Phillip P. Chan, Alan D. Sobel and Kathleen Bloch.

  • How many employees does Cytosorbents have?

    Cytosorbents has 65 employees.

  • What is Cytosorbents revenue?

    Latest Cytosorbents annual revenue is $15.2 m.

  • What is Cytosorbents revenue per employee?

    Latest Cytosorbents revenue per employee is $233.1 k.

  • Who are Cytosorbents competitors?

    Competitors of Cytosorbents include Terumo Medical, Terumo and Hollister.

  • Where is Cytosorbents headquarters?

    Cytosorbents headquarters is located at 7 Deerpark Dr, Monmouth Junction, South Brunswick Township.

  • Where are Cytosorbents offices?

    Cytosorbents has offices in South Brunswick Township and Berlin.

  • How many offices does Cytosorbents have?

    Cytosorbents has 2 offices.